Denali therapeutics announces appointment of nancy thornberry to board of directors

South san francisco, calif., jan. 11, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that nancy thornberry has joined the board of directors, effective january 8, 2021. ms. thornberry's extensive biotech leadership and pharmaceutical experience includes more than 30 years of development and discovery work in multiple disease areas, including diabetes and endocrinology.
DNLI Ratings Summary
DNLI Quant Ranking